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Abstract.  The effect of tumor promoters and growth 
factors on the synthesis of urokinase and urokinase 
mRNA in human carcinoma cells has been investi- 
gated. In urokinase-producing human carcinoma cells 
(A 1251), a 20-40-fold increase in urokinase mRNA 
level is obtained after treatment with I0 nM phorbol 
myristate acetate (PMA), a smaller effect (two- to 
fourfold) with 2 ng/ml platelet-derived growth factor 
(PDGF) and no effect with epidermal growth factor 
(EGF) (up to 50 nM). After treatment with PMA, 
urokinase mRNA level increases already at 30 min 
peaking 2-4 h thereafter. 
Cell line A431, which has an abnormally high num- 
ber of EGF receptors, shows the same response to 
PMA, but also responds to EGF (two- to fourfold 
increase in mRNA). The kinetics are similar to those 
of A1251. Nuclear transcription experiments show 
that the PMA-induced increase in urokinase mRNA is 
due to increased synthesis. 
The protein synthesis inhibitor, cycloheximide (10 
t~g/ml), also increases the level of urokinase mRNA. 
When both cycloheximide and PMA are used, super- 
induction is observed. This result may indicate that a 
short-lived protein negatively regulates the level of 
urokinase. 
The different efficiency of the effectors (PMA and 
PDGF better than EGF) and their kinetics, as well as 
the effect of cycloheximide on urokinase mRNA syn- 
thesis, (a) are reminiscent of the effect of PDGF and 
PMA on competence phase genes (Kelly, K., B. H. 
Cochran, C. D. Stiles, and P. Leder, 1983, Cell, 
35:603-610), (b) demonstrate that the synthesis of 
urokinase is part of the early cellular response to these 
factors, and (c) provide a preliminary insight in the 
overproduction of urokinase by primary malignant tu- 
mors and transformed cells in culture. 
U 
'ROKINASE  is one of the two well-characterized  types 
of plasminogen activator (PA),  z enzymes that cata- 
lyze plasminogen-dependent fibrinolysis. In cell cul- 
ture and in vivo, modulation of PA level has been shown to 
occur under a variety of physiological  and experimental stim- 
uli, indicating that these enzymes may play a central role in 
controlling extracellular proteolysis (reviewed  in reference 40). 
The human urokinase gene is transcribed into a 2,500-nu- 
cleotides-long mRNA (50), the product of which is a single- 
chain polypeptide of ~50,000 daltons (44). 
Increased production of PA is associated with most spon- 
taneous tumors (reviewed in reference 30). PA increase was 
shown to  be  an  early, transformation-dependent  effect of 
tumor viruses (16, 34,  41,  47). Recent  data indicate that 
urokinase may be a necessary requirement for the metastatic 
activity of one type of human tumor (33). 
In this paper we use the word urokinase to indicate in general the product of 
the urokinase plasminogen activator gene. The term pro-urokinase refers to the 
single-chain, 47,000-dalton, inactive form of urokinase. 
2 Abbreviations used in this paper:  EGF, epidermal growth factor; PA, plas- 
minogen activator; PDGF, platelet-derived growth factor; PMA, phorbol myr- 
istate acetate. 
Growth factors and receptors are believed to play an im- 
portant  role  in  oncogenic transformation.  Growth  factors 
have been shown to induce PA synthesis in several cell lines 
(10, 11, 19, 20, 24, 35). Phorbol esters also induce the synthesis 
of PA in normal and transformed cell lines (l l, 14,  18, 39, 
49, 52, 53). 
In this context, it seems very important to understand the 
molecular basis of  PA induction by growth factors and tumor 
promoters as a prerequisite for finding the link between PA 
production  and human neoplasia. In this  paper, we have 
investigated the effect of some growth factors and of a tumor 
promoter on the expression of the human urokinase gene in 
human carcinoma cells. Our results indicate that synthesis of 
urokinase mRNA is increased in transformed cells by factors 
which in normal cells act at the early competence phase like 
phorbol myristate acetate (PMA) (21), but not by epidermal 
growth factor (EGF) which acts later in the cell cycle. Analysis 
of the kinetics of induction shows this to be primary effect of 
PMA and not a consequence of its activity on cell growth, 
revealing a  close similarity to the induction  of the c-myc 
oncogene by the same factors (21). 
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Materials 
EGF (receptor grade) and J2~I-EGF  were obtained from Collaborative Research 
Inc. (Lexington, MA). PMA was obtained  by LC Services Co. (Woburn, MA). 
SDS gel electrophoresis-purified  platelet-derived growth factor (PDGF) was a 
kind gift of Dr. Rick Assoyan (Bethesda, MD). Cycloheximide was purchased 
from Sigma Chemical Co. (St. Louis, MO). [35S]Methionine, [JH]thymidine, 
and a)2P-deoxytriphosphates  and 32p-uridine-triphosphate were from the Ra- 
diochemical  Center  (Amersham  Corp.,  UK).  A kit  from  Betbesda Research 
Laboratories (Rockville, MD) was used for nick translations. 
Cell Culture 
Cell lines A1251 (42), A431 (13), and the A431 derivative clone  18 (3) were 
kept  in continuous culture  at 37"C in a  5%  CO2 atmosphere  in Dulbecco's 
modified minimal essential medium,  supplemented with 10% fetal calf serum 
and glutamine. 
For the analysis of urokinase  and urokinase  mRNA induction,  confluent 
cells were kept  18 h in serum-free medium  before any treatment.  When cells 
were labeled with [J~S]methionine, induction  was carried out in the labeling 
medium and the cells were incubated 4 or 18 h. Labeling medium consisted of 
methionine-free medium supplemented with 0.5% serum and [35S]methionine 
(0.25 mCi/ml).  At the end of the incubation,  the medium was harvested and 
centrifuged to remove cell debris, and the cells were lysed as described (54). 
For urokinase mRNA quantitation  cells were kept for different times in the 
presence of the effector, in medium containing 0.5% serum. 
PA Assay 
Plasminogen activator was assayed in Linbro multi-well plates coated with ~251- 
fibrin (46). Details of the technique are published elsewhere (14, 54). One unit 
of PA activity is defined as the amount of enzyme that causes the release of 5% 
of the  total  trypsin-solubilized radioactivity  in  1 h  at  37"C. All activity was 
dependent  on the presence of plasminogen.  When  present,  affinity-purified 
anti-urokinase  lgG was used at a concentration  of 0.5 t~g/ml. 
Protein  concentration  was measured  by the  method  of Lowry et al.  (26) 
using a standard solution of bovine serum albumin. 
Immunoprecipitation 
Immunoprecipitation  of medium or lysate was carried out in immunoprecipi- 
tation buffer (10 mM Tris-HCI [pH 7.51, 0.15 M NaCI, 0.1% SDS, 1% Triton 
X- 100, 0.5 % sodium deoxycholate,  I mM EDTA), as described previously (14). 
Samples were denatured  in B-mercaptoethanol  and loaded onto a  10%  SDS 
polyacrylamide gel according to Laemmli (22). At the end of the run, the gel 
was fixed in 10% acetic acid and fluorography performed as described (23). 
RNA Extraction and Analysis 
Preparation  of RNA,  electrophoretic  analysis,  blotting,  and  conditions  for 
hybridization  have been described elsewhere (50). Dot blot hybridization was 
carried out as described (28, 34). Nick-translated probes were human urokinase 
cDNA fragments (50) or ~2-microglobulin DNA (21, 36). 
Thymidine Incorporation 
Thymidine  incorporation  was quantitated  measuring  the  amount of TCA- 
precipitable [JH]thymidine incorporated  in a 2-h pulse. 
Nuclear Transcription Assay 
The synthesis of urokinase  mRNA was assayed in  nuclei  of A431 cells as 
described by Vannice et al. (48). 5 ×  l0  T  cells were treated with 30 ng/ml PMA 
for 3 h,  the  nuclei  isolated  and transcribed  in  the  presence  of 32P-uridine- 
triphosphate.  107 cpm of RNA were hybridized with 2.5 ug of either pHUK-8 
DNA (a 1.5-kb Pst-I fragment ofpHUK-1, 29), or to a cDNA clone of class I 
HLA-I  antigen (1.6 kb) (Boncinelli, E. and A, Simeone, unpublished  proce- 
dures). 
Results 
Effect of  EGF and PMA on Urokinase Synthesis in 
A431 andA1251 Cells 
Two human  carcinoma cell lines,  A1251  and  A431,  have 
been used. A1251 derives from a kidney carcinoma (42), and 
A431 from an epidermoid carcinoma of the vulva (13). It has 
already  been  reported that  EGF  increases the  fibrinolytic 
activity of A431  cells (18); we observed that PMA increases 
urokinase synthesis in A 1251 cells (!4). We now analyze in 
more detail the induction of PA in these cells by measuring 
the enzyme activity (Table I) and urokinase protein synthesis 
(Fig. 1). Table I shows that PMA (10 nM) increases urokinase 
level of not only A 1251 (14), but also of A431 cells. EGF (50 
nM) increases urokinase level in A431  cells only and has no 
effect on A1251  cells. All fibrinolytic activity is plasminogen 
dependent (data not shown) and is completely inhibited by 
monospecific antibodies directed towards human urokinase. 
This applies to both basal and induced levels of the enzyme. 
Table 1. Fibrinolytic Activity of  A431 and A1251 Cells 
Effects of  EGF and PMA 
A431 cells  A1251  cells 
Basal activity  Medium  955  361 
Cell lysate  367  100 
Total  1,322  461 
% inhibition by anti-  Total  100  100 
urokinase IgG* 
Fold increase by PMA 
% inhibition by anti- 
urokinase IgG 
Fold increase by EGF 
% inhibition by anti- 
urokinase lgG 
Total  4  8 
100  100 
Total  2  1 
100  100 
Fibrinolytic activity was measured in the medium or in the cell lysate by the 
a2~l-fibrin assay (47). Confluent  cultures of A431 and A1251 were incubated 
for 8 h in serum-free medium  with or without  l0 nM PMA or 50 nM EGF. 
The activity is expressed in arbitrary  units and related to equal amounts of 
cellular proteins as determined by the Lowry method (26). Fold increase is the 
ratio of the activity measured in the presence and absence of  the effectors. Total 
activity  indicates  the  sum  of medium  and  cell lysate  activities  measured 
separately. 
* 0.2 ug of affinity-purified rabbit anti-urokinase immunoglobulins. 
Figure  1.  lmmunoprecipita- 
tion  of [3SS]labeled  pro-uroki- 
nase  from  A431  cells.  Con- 
fluent  cells  were  treated  with 
tetradecanoyl-phorbol-acetate 
(10 nM), EGF (50 nM) or sol- 
vent,  for  18  h  in  methionine- 
free Eagle's medium and 0.25 
mCi/ml [35S]L-methionine. An 
equal number of trichloroace- 
tic  acid-precipkable  counts 
from the ceils' medium was im- 
munoprecipitated in each case 
and  applied  to  a  10%  SDS 
PAGE  after reduction with ~3- 
mercaptoethanol.  Lane  M 
shows  the  migration  of  the 
markers, the molecular weights 
of which are  indicated  to  the 
left. 
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exclusively due to urokinase. 
Urokinase  secreted  by A431  cells  has  been  labeled  with 
[3~S]L-methionine and immunoprecipitated  with  anti-uroki- 
nase IgG. A representative immunoprecipitation of urokinase 
from the  medium  of A431  cells  incubated  for  18  h  in  the 
absence and presence of EGF (50 nM) and PMA (10 riM) in 
serum-free medium is shown in Fig. 1. A single band with an 
apparent  molecular  mass  of ~48,000  daltons  is greatly in- 
creased upon both treatments.  Under the conditions used in 
this experiment, most ofurokinase is present in the medium 
(data not shown). 
As expected from the data of Table I, EGF has no effect on 
pro-urokinase synthesis in A 1251 cells (data not shown). This 
finding  is  not  due  to  the  absence  of EGF  receptors  from 
A1251  cell  membranes.  We have  estimated  the  number of 
EGF receptors on A 1251  and A431 cell membranes by mea- 
suring the binding of ~25I-EGF at 0*C and its competition by 
cold EGF.  A1251  cells have approximately three- to sixfold 
less  receptors  than  A431  cells;  i.e.,  a  "normal"  number  of 
EGF receptors (data not shown). A431  cells have an abnor- 
mally high  number  of EGF  receptors  (23).  A  quantitative 
radio-immunoprecipitation assay (Corti, A., G.  Cassani,  M. 
L. Nolli, and F. Blasi, manuscript in preparation) was used to 
study the kinetics of PMA and EGF effect on pro-urokinase 
synthesis  in  A431  cells.  In  summary,  maximal  induction 
reached threefold with 20 nM EGF and sixfold with  10 nM 
PMA.  Induction becomes evident  at early times in the cell 
lysate  (1-2  h)  and  later  in  the  medium  (4-6  h)  (data  not 
shown).  From all the data we conclude that the increase in 
fibrinolytic activity in A431 and A 1251 cells is due to an early 
increase in pro-urokinase synthesis. 
Urokinase mRNA Levels in A431 and A1251  Cells 
Are Increased by EGF, PMA, or PDGF 
Total cytoplasmic RNA isolated from confluent cells,  starved 
of serum for 18 h, was electrophoresed through an agarose- 
formaldehyde  gel,  blotted  onto  a  nitrocellulose  sheet,  and 
hybridized to a nick-translated cDNA fragment covering most 
of the urokinase mRNA (50). Northern analysis shows (Fig. 
2) that PMA (lanes A and B) or EGF (lanes C and D) increase 
urokinase  mRNA in  A431  cells.  PDGF  has  no  effect  (not 
shown). The higher molecular weight band, 2,500 nucleotides 
long, is the mature urokinase  mRNA (50).  A  second band, 
with  a  migration  slightly  faster  than  18S,  is  also  regularly 
observed. Whether it corresponds to a degradation product of 
urokinase mRNA or to a second mRNA species, remains to 
be investigated. We have previously reported that A 1251 cells 
also  respond  to  PMA  by  increasing  the  level  of urokinase 
mRNA (14). We now show that in these cells PDGF has the 
same effect (lanes E and F). The extent of induction has been 
estimated in several experiments by densitometer tracing. In 
A431 and A 1251  cells,  PMA increases the urokinase mRNA 
level by at least 20-fold, while the effect of EGF on A431  or 
of PDGF on A 1251  is only two- to threefold. The specificity 
of the effect has been tested by hybridizing parallel filters to a 
murine i32-microglobulin probe (36). No effect on ~2-micro- 
globulin  mRNA  has  been  observed  (data  not  shown).  As 
shown in Fig. 3, we have studied the effect of EGF and PMA 
on urokinase mRNA level of clone  18 variant of A431 cells, 
a  derivative  showing a  10-fold reduction in  the  number of 
EGF  receptors  (3).  While  EGF  has  no  effect  (not shown), 
Figure 2.  Northern  blot analysis of induced  urokinase  mRNA in 
A431 and A1251 cells. Total  cytoplasmic  RNA was isolated from 
confluent cells kept for 18 h in serum-free medium and treated for 4 
h with  10 nM PMA (B), or 50 nM EGF (D),  or 10 ng/ml PDGF 
(F). (Lanes A, C, and E) RNA from control  cells treated  with the 
same volume of solvent. (Lanes A-D) A431 cells. (Lanes E and F) 
A 1251 cells. The blotted filters were hybridized to a nick-translated 
urokinase  cDNA probe covering >75%  of the coding  region  (see 
text). 
Figure 3. Dot-blot  hybridization  analysis of the effect of PMA (10 
nM)  on  the  level of urokinase  mRNA  in  A431 clone  18  cells. 
Confluent cells were kept overnight in serum-free medium and then 
exposed to  10 nM  PMA  (+) or to the same  amount of dimetbyl 
sulfoxide solvent (-) for 3 h. Two quantities of RNA (0.4 and 4.0 ug) 
were filtered in duplicate through nitrocellulose paper and hybridized 
to a nick-translated probe of urokinase cDNA (see legend to Fig. 2). 
PMA still causes a ~ 15-30-fold increase in urokinase mRNA. 
The kinetics of urokinase mRNA induction by PMA have 
been measured by a dot-blot hybridization assay (Fig. 4). An 
~40-fold increase can be observed 2  h  after the addition of 
PMA to A 1251 cells with an at least fourfold increase already 
evident within 30 rain after addition of  PMA. Identical results 
have been obtained with A431 cells (not shown). 
Effect of  PMA and EGF on Thymidine Incorporation 
in A1251 Cells 
To correlate the effect of  PMA and EGF on urokinase mRNA 
induction with their effect on DNA synthesis, we have inves- 
tigated the effect of PMA and EGF on thymidine incorpora- 
tion  in  A1251  cells  under  the  same  conditions  in  which 
urokinase induction was studied.  10  S A 1251  cells,  incubated 
in medium containing 0.5%  fetal calf serum for 18 h  in 35- 
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urokinase  mRNA  induction  by  PMA. Confluent A1251  ceils were 
kept 18 h in serum-free medium and then PMA (10 nM) was added. 
Cells were harvested and total RNA was prepared at zero, 30, or 120 
min after addition of PMA. Two quantities of RNA (0.4 and 4  ug, 
respectively) were filtered in duplicate through a  nitrocellulose filter 
and hybridized to a nick-translated urokinase cDNA clone (see legend 
to  Fig.  2).  Numbers  to  the  left  indicate  the  incubation  times,  in 
minutes: those at the bottom indicate the amount of loaded RNA. 
Table II. Effect of  Serum Starvation, PMA, and EGF on 
Thymidine Incorporation ofA1251  Cells 
% Serum in preincubation  [aH]Thymidine 
medium*  Treatment*  incorporated  t 
10  None  1.22 
0.5  None  1.35 
0.5  10% FCS  1.26 
0,5  10 nM PMA  0.67 
0.5  20 nM EGF  0.97 
* 5 x  104 trypsinized cells were seeded in 35-mm plates in 4 ml with  10% fetal 
calf serum. After 6 h the medium was changed and cells preincubated for 14 h 
in medium containing the indicated amounts of serum. 
: After preincubation,  cells were treated as shown for 3  h,  then thoroughly 
washed with Dulbecco's modified minimal essential medium containing 0.5% 
serum and incubated in  medium containing 0.5%  serum for an additional 
12h. 
At the end of this period, cells were incubated in medium containing [~HI- 
methylthymidine (3 ~Ci/ml), 20 mM Hepes (pH 7), 1 mg/ml BSA~ glutamine, 
and 0.5% fetal calf serum at 37"C for 2 h. Monolayers  were washed,  1 ml of 
1 N  NaOH  was  added for  I  h  at  37"C, and  thymidine incorporation was 
measured counting the total  radioactivity  precipitated by 10% trichloroacetic 
acid. The results are expressed as counts incorporated ×  10-4/plate and are the 
average of three parallel determinations with <10% deviation. 
mm dishes, were treated with either PMA (10 nM), EGF (50 
nM), or 10% fetal calf serum, for 3 h. The cells were washed 
and the amount of [3H]thymidine incorporated in a 2-h pulse 
was assessed after 12 h. The results are reported in Table II. 
Serum  starvation  for  18  h  has  no effect  on  [3H]thymidine 
incorporation.  The  subsequent  addition  of  10%  fetal  calf 
serum also has virtually no effect. However, PMA and EGF 
cause a 50% and 30% inhibition, respectively. 
Effect of Cycloheximide on the Urokinase mRNA 
Expression  of several genes is rapidly induced by PDGF (5, 
21)  and  PMA (17). Inhibitors of protein  synthesis  lead  to 
superinduction of the PDGF-induced genes,  indicating that 
their expression  may be regulated  by some rapidly turning- 
over protein (18, 21). To determine whether urokinase mRNA 
is subject to the same kind of superinduction, the effect of 
cycloheximide on urokinase mRNA level was studied.  Con- 
fluent  A431  and  A1251  cells  were  treated  with  10  #g/ml 
cycloheximide; after 30 rain the cells were treated with EGF, 
PMA, or diluent for an additional 3 h. Fig. 5 shows the results 
obtained with A431  cells. Cycloheximide increases  the level 
Figure 5. Effect ofcycloheximide on urokinase mRNA in A431  cells. 
Confluent A431  cells (kept  in  serum-free medium  for  18  h)  were 
treated for 30 rain with 10 ug/ml cycloheximide prior to the addition 
of PMA (10 nM), EGF (50 nM), or diluent. Total cytoplasmic RNA 
was extracted after 3 h of incubation. 30 ug of RNA were electropho- 
resed in an  agarose-formaldehyde gel, blotted onto a  nitrocellulose 
filter,  and  hybridized  to  a  nick-translated  urokinase  cDNA  probe 
(legend to Fig. 2).  (A) Control cells. (B) Cycloheximide alone.  (C) 
EGF  alone,  (D)  Cycloheximide,  then  EGF,  (E)  PMA  alone.  (F) 
Cycloheximide, then PMA. 
of urokinase mRNA both in control and in EGF- or PMA- 
treated cells in which a superinduction is observed.  Identical 
results are obtained with A1251 cells and PMA. 
PMA Increases the Synthesis of Urokinase mRNA 
in A431 Cells 
To investigate whether the increase in urokinase mRNA level 
was due to increased  synthesis or to message stabilization,  we 
carried out nuclear transcription assays on control and PMA- 
treated A431 cells. Nuclei were transcribed in vitro (48) and 
the  32p-labeled RNA  was  hybridized  to  both  a  urokinase 
cDNA probe and to a class I HLA cDNA probe, in a dot-blot 
assay. The results are shown in Fig. 6. Hybridization to human 
HLA-1  cDNA was almost identical  with  PMA-treated and 
control RNA. On the contrary, hybridization to the urokinase 
probe was clearly increased  by PMA treatment. Counting of 
the spots in a  scintillation  counter shows that hybridization 
to  the  HLA-1  probes  is  increased  by  30%  by  the  PMA 
treatment, while hybridization to urokinase DNA is increased 
by almost 500%. 
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and  10 nM PMA-treated (B) A431  cells. 2.5 #g of pHUK-8 DNA (1) 
or human HLA-1 cDNA (2) were spotted onto the filters, which were 
then hybridized with 107 32p-cpm of nuclear RNA transcripts. 
Discussion 
Transcriptional Induction of the Urokinase Gene 
In this paper, we show (a) induction of fibrinolytic activity in 
two cell lines (A1251  and  A431)  in  which  both  basal and 
induced activities are due to the urokinase form of PA; (b) 
that the increases in PA activity by EGF and/or PMA depends 
on the increase in urokinase mRNA; (c) that EGF acts only 
on A431  and not on A 1251 cells, even though these are able 
to bind EGF; (d) that the increases in urokinase mRNA is a 
fast response of the cells, being approximately 10-fold higher 
as early as 30 min after the addition of PMA (and EGF in the 
A431  cells); (e) that protein synthesis is not required for the 
induction of urokinase mRNA. In fact, treatment of  cells with 
cycloheximide increases urokinase mRNA and enhances the 
effect of the inducers (superinduction). This raises the inter- 
esting possibility that the urokinase gene is controlled by a 
short-lived protein. (f) Increase of urokinase mRNA depends 
on the enhancement of transcription of the urokinase gene. 
Tumor promoter PMA  is a  better inducer than  EGF in 
A431  cells;  PMA and PDGF also induce urokinase mRNA 
synthesis in A1251  cells, whereas EGF has no effect. The lack 
of effect of EGF is not due to inability of these cells to bind 
the growth  factor since A 1251  cells have an  approximately 
normal number of EGF binding sites. 
The effect of EGF on A431  cell urokinase mRNA may be 
due to the abnormally high number of EGF receptors in these 
cells  (13).  If so,  EGF should  have  no  effect on  urokinase 
synthesis in  variants of A431  cells with a  lower number of 
EGF receptors. A431 derivative clone 18 (3) does not respond 
to EGF by increasing urokinase mRNA. The effect of PMA, 
on the other hand, is identical in A431, A1251, and clone 18 
cells.  Our  conclusion,  therefore,  is  that  urokinase  can  be 
induced by PMA and not by EGF, at least in the presence of 
a physiological number of EGF receptors. 
The small effect of PDGF on urokinase mRNA synthesis 
in  A1251  is also unexpected.  Epithelial cells are in fact not 
able to bind PDGF (as reviewed in reference 45). On the other 
hand,  many malignant cell lines,  including  A1251,  present 
nonrandom ectopic protein production (42). The response to 
PDGF may be due to ectopic synthesis of PDGF receptors. 
Induction of Urokinase mRNA Is a Primary 
Effect of  eMA 
PMA  is  known  to  increase  the  level  of several  mRNAs, 
including urokinase (2). Here we have shown that this induc- 
tion is due to increase in transcription of the urokinase gene 
(Fig.  6). In addition, we show that PMA, as EGF, acts early 
on  urokinase gene expression in  cell lines where  it fails to 
stimulate DNA synthesis (Table II). This suggests that uroki- 
nase synthesis is directly regulated by these effectors, or by 
events that follow immediately their binding to the cell, and 
is not a consequence of their effect on cell growth. Phorbol 
esters may exert both a mitogenic (8, 25) and a differentiating 
effect (6, 43) on cultured cells. In the former case a stimula- 
tion, and in the latter case an inhibition, of thymidine incor- 
poration  is  observed.  In A431  and  A1251  carcinoma cells, 
early induction of urokinase RNA by PMA is followed by an 
inhibition of thymidine incorporation (Table II). Therefore, 
there  does  not  seem  to  be  a  causal  connection  between 
urokinase induction and thymidine incorporation. In fact, in 
normal mouse bone marrow macrophages, PA induction by 
PMA is followed by a stimulation ofthymidine incorporation 
(20).  Similarly, EGF blocks growth of A431  cells  (where  it 
induces urokinase synthesis), but has no effect on the clone 
18 variant, in which it fails to induce urokinase. Finally, the 
induction  of urokinase by cycloheximide, which blocks cell 
growth  (Fig.  5),  shows that,  in  agreement with  the  former 
interpretation, protein synthesis is not required for urokinase 
mRNA induction. 
Urokinase Has Regulatory Features Similar 
to Competence Genes 
The following features of urokinase gene regulation in trans- 
formed cells are similar to those recently reported for several 
competence-phase genes, including c-rnyc (5, 21). (a) PDGF 
and PMA, mitogens active in the early competence phase of 
cell growth (15, 37), induce the synthesis ofurokinase mRNA. 
EGF, a mitogen acting later in the cell cycle, is a less effective 
inducer  in  A431  cells  and  is  inactive  in  A1251  cells.  (b) 
Induction of urokinase mRNA is an early effect of PMA or 
PDGF administration. (c) Cycloheximide induces the synthe- 
sis of urokinase mRNA and enhances the effect of PMA. 
The regulation ofc-rnyc has been studied in growth-arrested 
normal cells,  stimulated to grow by PDGF and  PMA (21); 
our results have been obtained in serum-independent human 
transformed cells.  However, induction  of PA  synthesis has 
been reported in normal macrophages stimulated to grow by 
PMA or colony-stimulating factor (20).  It seems, therefore, 
possible to propose that  the increase of urokinase in  trans- 
formed cells is due to a chronic stimulation of the urokinase 
gene by growth factors produced by tumor ceils,  i.e.,  by the 
loss of cell-cycle regulation of urokinase gene expression. 
Has Urokinase Any Role In Cell Growth and Cancer? 
Myra-y-Lopez et  al.  (29)  propose  that  PA  production  in 
malignant tumors is part of  the biosynthetic program induced 
by growth-stimulating hormones. We show that increase of 
urokinase mRNA is a direct effect of different growth effec- 
tors. Recent studies showing identity between oncogenes and 
Sloppel|i et al. Urokinase mRNA Induction by Tumor Promoters  1239 some growth  factors or their receptors (9,  10,  51)  and  the 
phenotypic coordinated transforming effect of three growth 
factor peptides (1) may provide a working hypothesis for this 
effect.  A  long-recognized association exists between PA pro- 
duction and human neoplasia (4, 7,  12, 27,  32,  33, 40). The 
role, if any, of PA in cancer is unknown. The hypothesis that 
is mostly supported by experimental facts is that PA controls 
extracellular proteolysis (40). In this respect, it is of the highest 
interest  that  anti-urokinase antibodies  block the  metastatic 
activity of a human tumor inoculated in the chorionallantoid 
chamber of the chick embryo (33).  Alternative or additional 
functions are not excluded, particularly those that propose an 
intracellular role for PA, like down-regulation of membrane 
receptors (18) or regulation of the structure of cellular cyto- 
skeleton (38). 
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